BlueSkeye AI, Nottingham, UK-based healthtech company, secured £3.4 million in funding to pursue its mission to improve people’s quality of life through its proprietary face and voice analysis technology.
The round was led by XTX Ventures, with participation from Foresight Group, Praetura Ventures, the University of Nottingham, and a consortium of high-net-worth individuals.
The funding will further accelerate BlueSkeye AI’s expansion across clinical and non-clinical health and wellbeing markets to transform patient pathways at scale.
As part of this investment, BlueSkeye AI will expand its activities with a physical presence in the North-West of England.
Professor Michel Valstar, Co-Founder and CEO at BlueSkeye AI, said: “The demand for alternative pathways to access mental healthcare is enormous, and continues to grow by the day. We’re committed to disrupting traditional approaches to healthcare to help improve the quality of people’s lives, and we’re particularly focused on the perinatal mental health sector. With the support of XTX Ventures, Foresight Group and Praetura Ventures, we’ll strengthen the rollout of new clinical trials and product development, and champion the benefits of technology for reinforcing healthcare provision on a national, regional and global basis.”
One key technology created by BlueSkeye is the B-Social Software Development Kit (SDK), which can be used to give social robots, virtual assistants, and any other interactive interface the ability to read a person’s facial expressions, head actions, and social gaze.
Company: BlueSkeye AI Ltd
Funding Month: October 2022
Lead Investors: XTX Ventures
Additional Investors: Foresight Group, Praetura Ventures, and the University of Nottingham
Company Website: https://www.blueskeye.com/
Software Category: Digital Health & Wellbeing
About the Company: Founded in 2019 by Professor Michel Valstar (CEO) and Dr. Anthony Brown (CTO) and Chief Machine Learning and Software Engineer Dr. Timur Almaev, Blueskeye is a health-tech company. BlueSkeye AI is poised to transform the diagnosis of mental health conditions and improve care in digital health and wellbeing and the automotive industry. It will significantly enhance the safety and wellbeing of the drivers and passengers of vehicles. BlueSkeye AI’s trademark, blending advanced research into expressive human behavior with specialist expertise in computer vision, machine learning, and AI, has many important use cases. BlueSkeye AI’s mission is to improve wellbeing and patient outcomes by building objective, accessible, scalable, and affordable mobile device apps for mental health monitoring and putting them in the hands of the public and medical professionals.